Visual compatibility of dobutamine with seven parenteral drug products
Dahlin, P.A.; Paredes, S.M.
American Journal of Hospital Pharmacy 37(4): 460; 464
1980
ISSN/ISBN: 0002-9289 PMID: 7377204 Document Number: 160778
Document emailed within 1 workday
Related Documents
Outman, W.R.; Mitrano, F.P.; Baptista, R.J. 1991: Visual compatibility of ganciclovir sodium and total parenteral nutrient solution during simulated Y-site injection American Journal of Hospital Pharmacy 48(7): 1538-1539Lor, E.; Takagi, J. 1990: Visual compatibility of foscarnet with other injectable drugs American Journal of Hospital Pharmacy 47(1): 157-159
Fong, P.A.; Ward, J. 1989: Visual compatibility of intravenous famotidine with selected drugs American Journal of Hospital Pharmacy 46(1): 125-126
Swenson, E.; Gooch, W.M.; Higbee, M.D. 1986: Visual compatibility of ceftizoxime sodium in four electrolyte injections American Journal of Hospital Pharmacy 43(9): 2242-2244
Martinez, J.F.; Trissel, L.A.; Gilbert, D.L. 1997: Compatibility of warfarin sodium with selected drugs and large-volume parenteral solutions International Journal of Pharmaceutical Compounding 1(5): 356-358
Strong, D.K.; Ho, W.; Nairn, J.G. 1989: Visual compatibility of vancomycin and heparin in peritoneal dialysis solutions American Journal of Hospital Pharmacy 46(9): 1832-1833
Zhang, Y.; Xu, Q.; Trissel, L.A.; Baker, M.B. 1999: Physical Compatibility of Calcium Acetate and Potassium Phosphates in Parenteral Nutrition Solutions Containing Aminosyn Ii International Journal of Pharmaceutical Compounding 3(5): 415-420
Benedict, M.K.; Roche, V.F.; Banakar, U.V.; Hilleman, D.E. 1988: Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection American Journal of Hospital Pharmacy 45(5): 1117-1118
Huss, P.; Miller, J.; Unverferth, D.V.; Leier, C.V. 1981: The new inotropic drug, dobutamine Heart and Lung: the Journal of Critical Care 10(1): 121-126
Trissel, L.A.; Martinez, J.F. 1994: Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection American Journal of Hospital Pharmacy 51(4): 495-499
Mutnick, A.H.; Souney, P.F. 1988: Dobutamine: a drug utilization evaluation Hospital Formulary 23(5): 461
Lanzarini, L.; Previtali, M.; Ferrario, M.; Mussini, A.; Poli, A.; Fetiveau, R.; Montemartini, C. 1992: Comparison of results of echo-dobutamine and ECG-dobutamine tests in the diagnosis of coronary disease Giornale Italiano di Cardiologia 22(8): 953-961
Trissel, L.A.; Parks, N.P.; Santiago, N.M. 1991: Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection American Journal of Hospital Pharmacy 48(10): 2186-2189
Outman, W.R.; Monolakis, J. 1991: Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection American Journal of Hospital Pharmacy 48(7): 1539-1541
Owsley, H.D.; Rusho, W.J. 1997: Compatibility of common respiratory therapy drug combinations International Journal of Pharmaceutical Compounding 1(2): 121-122
Wang, Y.C.; Kowal, R.R. 1980: Review of excipients and pH's for parenteral products used in the United States Journal of the Parenteral Drug Association 34(6): 452-462
Wollstadt, A.; Krämer, I.; Kamin, W. 2013: Physicochemical compatibility of nebulizable drug admixtures containing colistimethate and tobramycin Die Pharmazie 68(9): 744-748
Hoiberg, C.P. 1989: Aluminum in parenteral products: overview of chemistry concerns and regulatory actions Journal of Parenteral Science and Technology: a Publication of the Parenteral Drug Association 43(3): 127-131
Knapp, D.E.; Crosby, D.L.; Brandon, B.M.; Knapp, D.A. 1978: Can pharmacists influence drug prescribing? a look at eight of the top 25 drug products for 1976 American Journal of Hospital Pharmacy 35(5): 593-594
Mascoli, C.C.; Weary, M.E. 1979: Limulus amebocyte lysate (LAL) test for detecting pyrogens in parenteral injectable products and medical devices: advantages to manufacturers and regulatory officials Journal of the Parenteral Drug Association 33(2): 81-95